LEXX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $13k16.3k shares AddQ1 2026 $3.1k $0.78 $0.602
Jim SimonsRenaissance Technologies $9.6k15.6k shares ExitQ4 2025 $9.6k $0.617 $0.602
Jim SimonsRenaissance Technologies $9.6k15.6k shares AddQ4 2025 $3 $0.617 $0.602
Jim SimonsRenaissance Technologies $-63.4K ExitQ3 2024 $63k -- $0.602
Jim SimonsRenaissance Technologies $-63.4K ExitQ3 2024 $63k -- $0.602
BlackRockInvestor $70.8K AddQ2 2024 $71k -- $0.602

News

accessnewswire.comLexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underwayaccessnewswire.comJun 9

thenewswire.comLexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.thenewswire.comJun 9

thenewswire.comLexaria Attending the BIO International Convention, as part of a Broader Business Development Programthenewswire.comJun 3

accessnewswire.comLexaria Attending the BIO International Convention, as Part of a Broader Business Development Programaccessnewswire.comJun 3

accessnewswire.comLexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7accessnewswire.comMay 19

Trade LEXX

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.

CEO: Richard C. Christopher
IPO Date: Jan 12, 2021

Market Data

Open: $0.66
High: $0.719
Low: $0.6501
Volume: 110.6K
52W High: $1.55
52W Low: $0.46

Valuation

Market Cap: $14M
Enterprise Value: $8.6M

Financials

Free Cash Flow: $-10M
Revenue: $706k
Net Income: $-12M
Cash: $1.8M
Debt: $109k

Events

EarningsJul 13

EPS est. -0.06